Bristol-Myers' Opdivo succeeds in key stomach cancer study

(Reuters) - Bristol-Myers Squibb Co said on Thursday its blockbuster immunotherapy Opdivo helped patients with advanced stomach cancer live longer in a late-stage study, becoming the first drug of its kind to show a survival benefit in these patients.